672 results about "Pyran" patented technology

The present invention relates to a preparation method of an intelligent self-repairing, flame-retardant and light-resistant water-based polyurethane coating. The method comprises the following steps: preparing a self-made hyperbranched flame retardant and using it in the synthesis of a polyurethane prepolymer; cooling the mixture to 58° C., adding 2,2-dimethylolpropionic acid, reacting the mixture for 1 to 2 hours, adding 1 to 2 parts of a disulfide compound, reacting the mixture for 1 to 2 hours at 60 to 80° C., adding 1 to 2 parts of a hydrogen bonding agent, reacting the mixture for 1 hour at 60 to 80° C., adding 0.5 to 1.5 parts of a coumarin derivative, and reacting the mixture for 60 to 90° C. The mixture was stirred for 1-2 hours, and then spiropyran, diethanol monoisopropanolamine, and 0.01 parts of p-toluenesulfonamide were added, and the mixture was reacted at 50°C for 30 minutes. The temperature was lowered to 40-45°C, and 1-2 parts of triethylamine were added, and the mixture was reacted for 1-2 hours. The mixture was cooled to room temperature, and 60-65 parts of water were added. The mixture was stirred at a speed of 1800-2000 r / min for 0.5-1 hour to obtain an intelligent self-healing, flame-retardant, and light-resistant water-based polyurethane coating. The flame retardancy and self-healing properties of the obtained water-based polyurethane were significantly improved.

The invention discloses an antibacterial material rich in a bismuth metal organic framework and a preparation method thereof, the method comprises the following steps: adding an indole monomer and an alcohol monomer into a solvent, and then adding nitrosalicylaldehyde into the solvent to obtain a spiropyran compound; the preparation method comprises the following steps: adding humic acid into a binary solvent consisting of dioxane and butanol to obtain a mixed solution; the ratio of the mass of the humic acid to the volume of the binary solvent is (2-3): (20-40) g / ml; sequentially adding a bismuth source, 2-bromo-5-(trifluoromethyl) pyridine and 4-(trifluoromethyl) phenylboronic acid into the mixed solution to obtain a bismuth metal organic framework; and adding the spiropyran compound into the bismuth metal organic framework to obtain the antibacterial material rich in the bismuth metal organic framework. The antibacterial capability of the antibacterial material is improved.

The present invention provides the synthesis and application of a group of multiple stimulus-responsive aggregation-induced emission enhancement probes, belonging to the field of aggregation-induced emission materials. Through a simple three-step method, a D-π-A type molecular skeleton is constructed in the molecule, and a group of pyranone-type aggregation-induced emission enhancement probes are synthesized. This group of probes can undergo non-interfering changes in fluorescence color or intensity under multiple stimuli such as solvents, pressure, humidity, and pH. On the one hand, it makes up for the relatively single variety of AIE template molecules; on the other hand, it breaks through the technical barrier of single response of aggregation-induced emission probes, realizing the possibility that the same molecule can simultaneously respond non-interferingly to multiple external stimuli. The preparation method of this probe is simple, with high yield and sensitive and rapid fluorescence response, and is suitable for various application needs.

The invention discloses a near-infrared dichroic dye, a liquid crystal composition and application of the near-infrared dichroic dye and the liquid crystal composition. The structural general formula of the disclosed dichroic dye is as shown in formula I in the specification. According to the invention, a hydrogenated quinoline ring, a hydrogenated benzopyran ring and a hydrogenated naphthalene ring are introduced into a molecular skeleton, so that the novel near-infrared dichroic dye with high light stability, high solubility, high order parameter and high light modulation capability is obtained. Compared with the near-infrared dichroic dye disclosed in the prior art, the absorption band is further subjected to red shift, and the light modulation capability is remarkably improved; ordering parameters are greatly improved, and the application bottleneck is solved.

The invention discloses a low-concentration ether electrolyte adaptive to a high-voltage high-nickel ternary lithium ion battery, a preparation method of the low-concentration ether electrolyte and the lithium ion battery, and relates to the technical field of batteries. The ether electrolyte comprises a solvent and a solute; the solvent comprises an ether solvent, and is specifically at least one of 4-cyano tetrahydropyran, 2-(tetrahydro-2H-pyran-4-yl) acetonitrile, 2-methoxyacetonitrile, 2-ethyoxyl acetonitrile, 3-methoxypropionitrile, 3-ethyoxyl propionitrile, 3-butoxyl propionitrile, ethylene glycol bis (propionitrile) ether and 3-{2-[2-(2-cyano ethyoxyl) ethyoxyl] ethyoxyl} propionitrile. The ether solvent contains cyano groups, the strong electronegativity of the cyano groups enables the cyano groups to be coordinated with transition metal ions in the ternary material, and the cyano groups are preferentially adsorbed at the interface of the positive electrode material, so that the arrangement of solvent molecules at the interface has directivity, the proportion of ether oxygen bonds and carbon hydrogen atoms in double electric layers is reduced, and the performance of the positive electrode material is improved. And the sites which are easy to generate dehydrogenation reaction in the molecules are far away from the high-voltage positive electrode interface which is easy to generate oxidation reaction.

The invention relates to the technical field of organic synthesis, in particular to a method for constructing Orforglipron tetrahydropyran ring chirality through enzyme catalysis, which comprises the following steps: step S1, taking SM1 as a raw material, and carrying out hydrolysis resolution in a solvent, a buffer salt system and enzyme catalysis to obtain a chiral pure intermediate INT-1; step S2; performing ring closing on the INT-1 through Grignard reaction to synthesize a lactone intermediate; s3, carrying out Diball-H reduction, quenching, dichloromethane extraction and anhydrous sodium sulfate drying on the INT-4, and then reducing the INT-4 by using triethyl silane to obtain an intermediate INT3; step S4, coupling the INT-3 in the presence of a catalyst and a ligand to obtain an intermediate INT-4; step S5, carrying out deprotection and salification on the INT-4 to obtain an intermediate INT5; s6, closing an indole ring from INT5 to obtain a compound of which the general formula is A; chirality is constructed through enzyme catalysis, isomer impurities do not need to be split and separated through SFC when the chirality is constructed, the loss is reduced, the yield is increased, and a target product is obtained with high chiral selectivity; meanwhile, the cost is relatively reduced, and the cost is saved.

A carbon sorbent for removing carbon dioxide from a gaseous material includes a surface composition including carbon, nitrogen, and oxygen. The nitrogen atoms at the surface of the carbon sorbent may be present in pyridone, pyrrole, and pyridine. The surface of the carbon sorbent may include lactone groups and pyrone groups. The carbon sorbent may have a bulk density greater than about 0.40 grams per cubic centimeter. The carbon sorbent may be formed using amino acids to provide the nitrogen for the carbon sorbent. In addition, the use of processing aids during the formation of the carbon sorbent facilitates the formation of a denser carbon sorbent. Related methods of forming the carbon sorbent and pellets of the carbon sorbent are also disclosed.

A polishing liquid for CMP, containing: abrasive grains; an additive; and water, in which the abrasive grains include cerium-based particles, a zeta potential of the abrasive grains is negative, the additive includes (A1) a 4-pyrone-based compound represented by General Formula (1) below, and a pH is 5.0 or more. A polishing liquid for CMP, containing: abrasive grains; an additive; and water, in which the abrasive grains include cerium-based particles, a zeta potential of the abrasive grains is negative, the additive includes (A2) a picolinic acid compound, and a pH is 5.0 or more.[In the formula, X11, X12, and X13 are each independently a hydrogen atom or a monovalent substituent.]

The invention provides a preparation method of a (S)-5-(2, 2-dimethyl tetrahydro-2H-pyran-4-yl)-N-methyl-N-phenyl-1H-indole-2-formamide compound, which comprises the following steps: by taking a compound 1 as an initial raw material, reacting the compound 1 with a boric acid ester reagent to obtain a boric acid ester compound 2; the method comprises the following steps: by taking a compound 3 as an initial raw material, reducing carbonyl through enzyme catalysis to obtain a compound 4, then protecting alcoholic hydroxyl through a sulfonylation reagent to obtain a compound 5, and finally, directly coupling the compound 5 with a compound 2 under the action of a catalyst to obtain a target product compound 6. The whole process is low in experimental condition requirement, simple to operate, high in yield and suitable for process amplification.

This disclosure provides redox cyclable molecules for energy storage. These molecules belong to either the 4H-pyran-4-ylidene family or include a six-membered aromatic ring with one nitrogen atom at position 1 (pyridinium family) or two nitrogen atoms at positions 1 and 4 (pyrazinium family) or at positions 1 and 3 (pyrimidinium family). Molecules in these families are used as analytes in redox flow batteries.

A carbon sorbent for removing carbon dioxide from a gaseous material includes a surface composition including carbon, nitrogen, and oxygen. The nitrogen atoms at the surface of the carbon sorbent may be present in pyridone, pyrrole, and pyridine. The surface of the carbon sorbent may include lactone groups and pyrone groups. The carbon sorbent may have a bulk density greater than about 0.40 grams per cubic centimeter and may exhibit a carbon dioxide capacity of at least 11.0 weight percent at 30° C. and 760 mmHg. The carbon sorbent may be formed using amino acids to provide the nitrogen for the carbon sorbent. In addition, the use of processing aids during the formation of the carbon sorbent facilitates the formation of a denser carbon sorbent. Related methods of forming the carbon sorbent and pellets of the carbon sorbent are also disclosed.

The present invention relates to the technical field of organic synthesis, and specifically relates to a method for constructing the chirality of a pyran ring in Orforglipron by means of enzymatic catalysis, the method comprising the following steps: step S1, by using SM1 and SM2 as starting materials, carrying out a reaction under the action of a palladium catalyst and a ligand to obtain INT-1; step S2, under the catalysis of Pd / C, subjecting INT-1 to double bond hydrogenation reduction to obtain INT-2; step S3, in the presence of a solvent, a buffer salt system and enzymatic catalysis, subjecting INT-2 to hydrolysis and resolution to obtain a chirally pure intermediate INT-3; step S4, subjecting INT-3 to a Grignard reaction for cyclization, so as to synthesize a lactone intermediate INT-4; and step S5, subjecting INT-4 to reduction by means of Dibal-H, quenching same, performing extraction with dichloromethane, drying same with anhydrous sodium sulfate, and then performing reduction by means of triethylsilane to obtain a compound of general formula A. In the present invention, the chirality is constructed by means of enzymatic catalysis without the need of SFC resolution for separating isomeric impurities during the construction of the chirality, thereby reducing losses and improving yield, obtaining the target product at high yield and high chiral selectivity, and further saving expenses and reducing costs.

The application discloses a pyrano pyridine compound, a preparation method, a pharmaceutical composition and application thereof. The application provides a compound as shown in formula (I), a pharmaceutically acceptable salt or a stereoisomer thereof, the compounds have a strong inhibitory effect on aldosterone synthase, have little influence on cortisol synthase, have high selectivity and high safety, and can be used for preventing and / or treating various diseases related to aldosterone.

2-diarylmethyl-4-aminotetrahydropyran derivatives are disclosed. The compounds include the following genus:or a pharmaceutically acceptable salt thereof. The compounds activate cellular PP2A, suppress oncogenic kinase signaling and negatively regulate MYC and MYCN in cancer. The compounds also induce FOXO transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.

The invention discloses a double-targeting probe and a preparation method and application thereof.The structure of the double-targeting probe is shown in the formula I. The double-targeting probe has the beneficial effects that SO2 can be monitored in the cell apoptosis process, the dynamic change of SO2 between mitochondria and lipid droplets in cells can be tracked, the core structure of the probe MLR is based on a coumarin part, and the core structure of the probe MLR can be used for detecting the apoptosis of the cells. The probe MLR is connected with a benzopyran cation structure specially designed for detecting SO2, SO2 generated in the death process of copper enables charges of a cation part in the probe MLR to be redistributed, a Michael addition reaction of SO2 and carbon-carbon double bonds is triggered, a fluorescence signal of the probe is changed, and the fluorescence signal is detected. The design of the probe provides a new tool for monitoring key biochemical changes in the copper death process, and is helpful for deeply understanding the molecular mechanism of copper death.

A carbon sorbent for removing carbon dioxide from a gaseous material includes a surface composition including carbon, nitrogen, and oxygen. The nitrogen atoms at the surface of the carbon sorbent may be present in pyridone, pyrrole, and pyridine. The surface of the carbon sorbent may include lactone groups and pyrone groups. The carbon sorbent may have a bulk density greater than about 0.40 grams per cubic centimeter. The carbon sorbent may be formed using amino acids to provide the nitrogen for the carbon sorbent. In addition, the use of processing aids during the formation of the carbon sorbent facilitates the formation of a denser carbon sorbent. Related methods of forming the carbon sorbent and pellets of the carbon sorbent are also disclosed.

This disclosure provides compounds of Formula ( AA ) Formula ( A ), Formula ( I ) (e.g., Formula ( I-a1 )), Formula ( II ) (e.g., Formula ( II-1 ), ( II-a ), ( II-a1 ), ( II-a2 ), or ( II-a3 )), Formula ( III ) (e.g., Formula ( III-1 )), Formula ( IV ) (e.g., Formula ( IV-a ), ( IV-a1 ), ( IV-b ), ( IV-b1 ), or ( IV-c )), or Formula ( B ) (e.g., Formula ( B-1 )), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein. In some embodiments, the KRas protein has a dysregulation (e.g., the KRas protein is mutated or amplified). These compounds are useful, for example, for treating a disease, disorder, or condition in which increased and / or sustained (e.g., excessive) KRas activation, for example, KRas activation associated with a mutant KRas protein, contributes to the pathology and / or symptoms and / or progression of the disease, disorder, or condition (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing compounds as disclosed herein, or pharmaceutically acceptable salts thereof, and methods of using and making the same.

The present disclosure relates to crystal forms of a triazine dione derivative and a preparation method therefor. Specifically, the present disclosure relates to different crystal forms of (S)-6-((1-(2-fluoro-5-methylphenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione and a preparation method therefor. The crystal forms of (S)-6-((1-(2-fluoro-5-methylphenyl)ethyl)amino)-3-(tetrahydro-2H-pyran-4-yl)-1,3,5-triazine-2,4(1H,3H)-dione provided by the present disclosure have good stability and can be better used for clinical treatment.

It is disclosed a class of pyrimidopyran compounds substituted with piperazine bridge and their applications thereof, such as compounds of Formulae (I''), (I'), or (I), stereoisomers thereof, or pharmaceutically acceptable salts thereof.

A polishing liquid containing: abrasive grains; an additive; and water, in which the additive includes (A1) a compound having two or more nitrogen atoms to which a hydroxyalkyl group is bonded and (B) a 4-pyrone-based compound represented by General Formula (1) below. A polishing liquid containing: abrasive grains; an additive; and water, in which the additive includes (A2) a polyglycerol and (B) a 4-pyrone-based compound represented by General Formula (1) below.[In the formula, X11, X12, and X13 are each independently a hydrogen atom or a monovalent substituent.]

Described is small molecule 6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)-4-(tetrahydro-2H-pyran-4-yl)quinolin-2-amine (MS152) that inhibits methyltransferases G9a / EHMT2. This inhibitor can be used for the treatment of patients with G9a / EHMT2 related diseases such as Prader-Willi Syndrome and Alzheimer's Disease. Formula (I).

A glycoside drug oral preparation for treating cerebral ischemic stroke during the recovery period and a preparation method therefor. The glycoside drug is (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-(4-methoxyphenyl)butoxy)tetrahydro-2H-pyran-3,4,5-triol. The oral preparation can provide a high drug loading capacity, release the drug within a short time period, and ensure rapid drug dissolution, and the prepared tablet has high stability, involves a simple preparation process and is suitable for large-scale industrial production.

The application relates to a pyrone-based chelating resin, a preparation method thereof and a method for removing impurities. The main chain skeleton of the pyrone-based chelating resin is a styrene-based adsorption resin, and at least one pyrone functional group is branched on the side chain. The multi-oxygen structure of the pyrone functional group and the nitrogen atom on the main chain skeleton can produce strong coordination with aluminum ions, and a stable six-membered ring chelate is formed through a chelation reaction, thereby showing excellent selective aluminum removal performance. Meanwhile, the pyrone functional group has acid-base properties, can undergo ion exchange reaction or physical adsorption with organic matters, and thus can effectively remove TOC in a water environment. Therefore, by using the pyrone-based chelating resin provided in the application, the aluminum ions and TOC in a rare earth solution can be efficiently removed through the synergistic cooperation of the multi-oxygen coordination effect and the selective ion exchange capacity, and the loss rate of the rare earth ions is obviously reduced.

The application belongs to the field of compound synthesis, and discloses a kind of compound containing seven-membered lactam and pyrone skeleton and its construction and application, and the chemical structure is shown in the following, wherein R1 is selected from any one of hydrogen, alkyl, halogen;R2 is selected from any one of alkyl, aryl;R3 is selected from any one of hydrogen, phenyl.The seven-membered lactam and pyrone skeleton has good drug activity, and can be used for preparing antitumor drugs.The application also discloses a construction method of the seven-membered lactam and pyrone skeleton.The construction method of the seven-membered lactam and pyrone skeleton has the advantages that raw materials and catalysts are cheap and easy to obtain, operation is simple and convenient, and the universality of substrates is wide.

Provided herein are compounds of Formula (II) (e.g., Formula (II-a), (II-b), (II-a1), (II-b1), (II-a2), (II-b2), (II-3), (II-a3), (II-4), (II-a4), (II-5), (II-a5), (II-6), (II-a6), (II-7), (II-a7), (II-7), or (II-a8)), Formula (III) (e.g., Formula (III-1), (III-2), (III-3), (III-4), (III-5), (III-6), (III-7), or (III-8)), Formula (IV) (e.g., Formula (IV-a), (IV-b), (IV-c), (IV-a1), (IV-b1), (IV-a2), (IV-b2), (IV-a3), (IV-b3), (IV-a4), (IV-b4), (IV-a5), (IV-b5), (IV-a6), (IV-b6), (IV-a7), (IV-b7), (IV-a8), or (IV-b8)), Formula (V) (e.g., Formula (V-a) or (V-b), (V-a1), (V-c), (V-d), (V-b1), (V-a2), (V-b2), (V-a3), or (V-b3)), Formula (VI) (e.g., Formula (VI-a), (VI-b), (VI-c), (VI-d), or (VI-e))), or Formula (A) (e.g., Formula (I-a1)), or pharmaceutically acceptable salts thereof, that inhibit a KRas protein (e.g., a dysregulated KRas protein (e.g., a mutated or amplified KRas protein)). This disclosure also provides compositions containing the compounds as provided herein, or pharmaceutically acceptable salts thereof, as well as methods of using and making the same.

The invention belongs to the field of medical chemistry, and relates to a benzopyrone compound, a benzopyrone composition and application of the benzopyrone compound and the benzopyrone composition in preparation of a medicine for treating hyperuricemia. The chemical structure is as shown in formula I; in the formula, R1 is fluorine or hydrogen; r2 is fluorine or hydrogen; r3 is hydrogen, nitryl or tertiary butyl; r4 is hydrogen, fluorine or trifluoromethyl; and R1, R2, R3 and R4 are not hydrogen at the same time. The benzopyrone compound provided by the invention has good inhibitory activity on XOD, and can reduce the level of uric acid, thereby being beneficial to treatment of hyperuricemia.

This invention provides a method for screening β-galactosidase inhibitors, belonging to the field of pharmaceutical technology. The first step of this method uses fluorescence sensing technology to rapidly identify natural products with β-Gal inhibitory activity. The principle is based on the fluorescence quenching property of p-nitrophenol (PNP) on sulfur quantum dots (SQDs); β-Gal catalyzes the hydrolysis of p-nitrophenyl-β-D-galactopyranoside (PNPG) to generate the specific product PNP; in the presence of β-Gal, PNPG can be enzymatically catalyzed to generate PNP, quenching the fluorescence of SQDs; when screened for β-Gal inhibitory activity, the fluorescence of SQDs can be restored. The second step uses affinity chromatography to capture components in samples with β-Gal inhibitory activity. This method involves immobilizing β-Gal on a support material, eluting with a solvent to obtain components that can bind to β-Gal, and then using liquid chromatography-mass spectrometry (LC-MS) to identify the components. This method can rapidly and accurately screen β-Gal inhibitors from natural products.

The objective is to provide a diol-containing composition that enables the stable production of polycarbonate diol compositions for obtaining polyurethanes suitable for use in paints, coatings, and adhesives. [Solution] A diol-containing composition comprising a diol compound (4) represented by the following general formula (IV) and a tetrahydropyran compound (3-1) represented by the following general formula (III-1). [Formula 1] JPEG2026054816000039.jpg567 (In the above general formula (IV), n is an integer between 3 and 6.) [chemical 2] JPEG2026054816000040.jpg1572 (In the above general formula (III-1), R1 is a C2-C12 alkyl group or hydrogen atom, which may have substituents or heteroatoms.) A polycarbonate diol composition comprising the aforementioned diol-containing composition and a carbonate-based compound as raw materials.

This invention discloses an ERβ-targeted hydrogen peroxide-responsive near-infrared fluorescent probe, its preparation method, and its applications, belonging to the field of medical technology. The fluorescent probes of this invention are dicyanomethylene-4H-benzodihydropyran compounds P1 and P2 containing borate ester groups, with the following structural formula. These fluorescent probes use DCM-OH as a backbone, acting as both a fluorophore and an ERβ ligand. The borate ester group is the H2O2 responsive group. The introduction of the borate ester group disrupts the push-pull effect of the DCM-OH fluorophore, preventing fluorescence emission. However, in a high-concentration H2O2 environment, the borate ester group is specifically cleaved by H2O2, subsequently exhibiting strong initiation fluorescence and enabling tumor imaging in vitro and in vivo. This invention brings new opportunities for the diagnosis and research of prostate cancer.